Market Trends– category –
-
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Novo Nordisk’s CagriSema Achieves Over 22% Weight Loss in Phase 3 Trials: Synergistic Benefits of GLP-1 and Amylin Analog
Life Science Daily News Global Overview Novo Nordisk's CagriSema, a combination therapy featuring a GLP-1 receptor agonist and the amylin analog cagrilintide, demonstrated over 22% weight reduction in Phase 3 trials. Specifically, the RE... -
Divi’s Labs: The ‘TSMC of Pharma’ for Peptides? GLP-1 Demand Elevates Manufacturing to Strategic Imperative
Antifragile Thinking Global Overview The surging global demand for GLP-1 therapeutics has transformed peptide manufacturing into one of the most strategically critical areas within the CDMO sector. India's Divi's Labs stands out as a key... -
Small Molecule Drug CDMO Market Sees Strong Growth, Driven by HPAPI and Continuous Manufacturing; WuXi AppTec Leads
OpenPR Global Overview The small molecule drug CDMO market is experiencing robust growth, fueled by increased outsourcing from pharmaceutical and biotech companies. Key drivers include investments in specialized facilities for highly pot... -
The Modern CDMO: A Strategic Blueprint for Pharmaceutical Leaders in a Complex Era
Agnopharma Global Overview This guide outlines the evolution of CDMOs from traditional CMOs, emphasizing their indispensable role in contemporary drug development. Modern CDMOs offer integrated solutions from process development to comme... -
GLP-1 Drug Manufacturing: Global Capacity Expansion and Tech Transfer Accelerate to Meet Soaring Demand
IntuitionLabs Global Overview The unprecedented surge in demand for GLP-1 therapeutics is driving a rapid global expansion of manufacturing capacity and technology transfer strategies in the pharmaceutical industry. Novo Nordisk is inves... -
Amgen Advances MariTide Obesity Drug into Phase 3 MARITIME Program, Targeting Infrequent Dosing for Market Differentiation
Sahm Capital USA Overview Amgen has advanced maridebart cafraglutide (MariTide), its investigational obesity treatment, into the Phase 3 MARITIME development program. MariTide is an antibody-peptide conjugate designed with a dual mechani... -
CPHI Japan 2026 Highlights Technical Challenges in Peptide Development: GLP-1 Demand Drives Focus on Sustainable Manufacturing
AmbioPharm Japan Overview The CPHI Japan 2026 conference underscored the increasing complexity of peptide drug development and the rising technical expectations for CDMOs. Global demand for GLP-1 agonists is creating a significant bottle... -
Global and Korean Pharma Intensify Race for Next-Gen Oral Obesity Drugs: GLP-1/GIP Dual Agonists and Microneedle Patches Emerge
Chosun Biz South Korea Overview The 2026 European Congress on Obesity highlighted intensified global competition in next-generation oral obesity drug development. Viking Therapeutics announced positive Phase 2 results for its oral GLP-1/... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr...
